However, a meta-analysis of randomized controlled phase 3 trials of belimumab in the treatment of SLE, including 554 SLE patients found that patients with increased baseline levels of IFN were more likely to respond to therapy with belimumab than those with lower baseline IFN levels (Wilkinson et al., 2020). Here, IFNA1 is linked to systemic lupus erythematosus.